Thymosin Alpha-1 dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 1.6 mg vial reconstituted with 1 mL bacteriostatic water gives 1.6 mg/mL. A 1.6 mg dose equals 100 units on a U100 insulin syringe (full syringe capacity).

   Open tool →
2. 2

   Measure the dose

   Typical Thymosin Alpha-1 dose is 1.6 mg (Label dose 1.6 mg twice weekly. Off-label compounded protocols mirror this schedule.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 2x weekly. Half-life of 2 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Approved indications use defined courses: 6 months for hepatitis B, 12 months for hepatitis C, individualized for oncology. Off-label immune-support courses typically run 4 to 12 weeks.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: mild injection-site irritation (rare); transient mild fatigue (rare); occasional headache (rare). Stop or reduce dose if tolerability breaks down.

Why this dose

Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.

The typical dose (1.6 mg) reflects Label dose 1.6 mg twice weekly. Off-label compounded protocols mirror this schedule.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Thymosin Alpha-1 is administered via the subcutaneous or intramuscular routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose.

Onset of action runs around 24 hours after administration. Peak effect lands near 1 weeks post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: ~2 hour plasma half-life with durable downstream immune effects supporting twice-weekly dosing.

Cycling and tolerance

Approved indications use defined courses: 6 months for hepatitis B, 12 months for hepatitis C, individualized for oncology. Off-label immune-support courses typically run 4 to 12 weeks.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
• Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
• Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
• Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
• Standard label dose: 1.6 mg subcutaneously twice weekly
• Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side effects and interactions

Common side effects

• mild injection-site irritation (rare)
• transient mild fatigue (rare)
• occasional headache (rare)

Notable interactions

• calcineurin inhibitors (cyclosporine, tacrolimus) (major): theoretical destabilization of immunosuppression; avoid
• antimetabolites (azathioprine, mycophenolate) (major): theoretical destabilization of immunosuppression; avoid
• interferon-alpha (minor): additive immune effect; used clinically in approved combination protocols
• vaccine administration (minor): may augment vaccine response in elderly or immunocompromised; coordinate with clinician

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Thymosin Alpha-1 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

unknown

DEA / Rx

Rx only via international approval or US compounding (no controlled-substance schedule)

Pregnancy

Not recommended; insufficient data

Legal status

Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List

Do not use if

• pregnancy
• lactation
• active organ transplant rejection therapy
• systemic immunosuppression for autoimmune disease (relative)
• severe active autoimmune disease (caution)

Related research